Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation

Journal of Neuro-Oncology

Volumn 107, Issue 1, 2012, Pages 61-67

  Van Nifterik, Krista A ^a   Van Den Berg, Jaap ^a   Slotman, Ben J ^a   Lafleur, M Vincent M ^a   Sminia, Peter ^a   Stalpers, Lukas J A ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

C Radiation; Glioma cells; Temozolomide; Trimodal treatment; Valproic acid

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; VALPROIC ACID; ALKYLATING AGENT; ANTICONVULSIVE AGENT; DACARBAZINE; DRUG DERIVATIVE; RADIOSENSITIZING AGENT;

ARTICLE; ASTROCYTOMA CELL; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; GAMMA RADIATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; INCUBATION TIME; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; BRAIN TUMOR; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; GLIOMA; PATHOLOGY; TUMOR CELL CULTURE;

ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL PROLIFERATION; DACARBAZINE; GAMMA RAYS; GLIOMA; HUMANS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; VALPROIC ACID;

EID: 84861674267     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0725-z     Document Type: Article

References (42)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
2. Stupp R, Hegi ME, Mason WP et al (2009) European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
3. Kaina B, Ziouta A, Ochs K et al (1997) Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex ? and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat Res 381:227-241
4. D'Atri S, Tentori L, Lacal PM et al (1998) Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54:334-341
5. Hirose Y, Katayama M, Stokoe D et al (2003) The p38 mitogenactivated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 23:8306-8315
6. Brennand J, Margison GP (1986) Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene. Proc Natl Acad Sci USA 83:6292-6296
7. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307
8. Hegi ME, Diserens AC, Godard S et al (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871-1874
9. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
10. Van Rijn J, Heimans JJ, van den Berg J et al (2000) Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47:779-784
11. Chakravarti A, Erkkinen MG, Nestler U et al (2006) Temozolomide- mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 12:4738-4746
12. Van Nifterik KA, van den Berg J, Stalpers LJ et al (2007) Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 69:1246-1253
13. Kil WJ, Cerna D, Burgan WE et al (2008) In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 14:931-938
14. Göttlicher M, Minucci S, Zhu P et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978
15. Kostrouchová M, Kostrouch Z, Kostrouchová M (2007) Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 53:37-49
16. Phiel CJ, Zhang F, Huang EY et al (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741
17. Camphausen K, Scott T, Sproull M et al (2004) Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 10:6066-6071
18. Kim JH, Shin JH, Kim IH (2004) Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 59:1174-1180
19. Chinnaiyan P, Vallabhaneni G, Armstrong E et al (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62:223-229
20. Entin-Meer M, Rephaeli A, Yang X et al (2005) Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol Cancer Ther 4:1952-1961
21. Karagiannis TC, Harikrishnan KN, El-Osta A (2005) The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A. X. Cancer Biol Ther 4:787-793
22. Kim IA, Shin JH, Kim IH et al (2006) Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res 12:940-949
23. Entin-Meer M, Yang X, VandenBerg SR et al (2007) In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro Oncol 9:82-88
24. Karagiannis TC, Kn H, El-Osta A (2006) The epigenetic modifier, valproic acid, enhances radiation sensitivity. Epigenetics 1:131-137
25. Chen X, Wong P, Radany E, Wong JY (2009) HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 24:689-699
26. Blattmann C, Oertel S, Ehemann V et al (2010) Enhancement of radiation response in osteosarcoma and rhabomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 78:237-245
27. Debeb BG, Xu W, Mok H et al (2010) Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 76:889-895
28. Camphausen K, Cerna D, Scott T et al (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114:380-386
29. Chinnaiyan P, Cerna D, Burgan WE et al (2008) Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14:5410-5415
30. Detich N, Bovenzi V, Szyf M (2003) Valproate induces replication- independent active DNA demethylation. J Biol Chem 278:27586-27592
31. Balmforth AJ, Ball SG, Freshney RI et al (1986) D-1 dopaminergic and beta-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocytoma cell line G-CCM. J Neurochem 47:715-719
32. Van Nifterik KA, van den Berg J, van der Meide WF et al (2010) Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer 103:29-35
33. Franken NA, Rodermond HM, Stap J et al (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315-2319
34. Kim MS, Blake M, Baek JH et al (2003) Inhibition of histonedeacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291-7300
35. Ciusani E, Balzarotti M, Calatozzolo C et al (2007) Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. Oncol Res 16:453-463
36. Das CM, Aguilera D, Vasquez H et al (2007) Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 85:159-170
37. Sasai K, Akagi T, Aoyanagi E et al (2007) O6-methylguanine- DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies. Mol Cancer 6:36
38. Fu J, Shao CJ, Chen FR et al (2010) Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol 12:328-340
39. Ständer M, Dichgans J, Weller M (1998) Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells. J Neurooncol 37:191-198
40. Oberndorfer S, Piribauer M, Marosi C et al (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72:255-260
41. Grewal J, Dellinger CA, Yung WK (2007) Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 356:1591-1592
42. Neyns B, Hoorens A, Stupp R (2008) Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. Acta Neurol Belg 108:131-134